Measuring dose-related efficacy of eptinezumab for migraine prevention: Post hoc analysis of PROMISE-1 and PROMISE-2

被引：0
作者：
Apelian, R. G. [1 ]
Boyle, L. [2 ]
Hirman, J. [3 ]
Asher, D. [4 ]
机构：
[1] Huntington Headache & Neurol, Arcadia, CA USA
[2] Lundbeck LLC, Deerfield, IL USA
[3] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA
[4] Lundbeck LLC, Deerfield, IL USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-181
引用
收藏
页码：151 / 152
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
    Lipton, Richard B.
    Goadsby, Peter J.
    Smith, Jeff
    Schaeffler, Barbara A.
    Biondi, David M.
    Hirman, Joe
    Pederson, Susan
    Allan, Brent
    Cady, Roger
    NEUROLOGY, 2020, 94 (13) : E1365 - E1377
  • [22] Migraine-Free Months in Patients with Episodic or Chronic Migraine Treated with Eptinezumab: Results from the PROMISE-1 and PROMISE-2 Trials
    Winner, P. K.
    McAllister, P.
    Cady, R.
    Snapinn, S.
    Hirman, J.
    Kassel, E.
    HEADACHE, 2019, 59 : 162 - 162
  • [23] Consistent reductions in migraine frequency with eptinezumab treatment in patients with migraine stratified by intrinsic factors: subgroup analyses of PROMISE-1 and PROMISE-2
    Janelidze, Marina
    Giorgadze, Gvantsa
    Cady, Roger
    Snapinn, Steve
    Hirman, Joe
    Kassel, Eric
    JOURNAL OF HEADACHE AND PAIN, 2019, 20
  • [24] Eptinezumab Results for the Prevention of Episodic Migraine over One Year in the PROMISE-1 (PRevention of Migraine via Intravenous Eptinezumab Safety and efficacy-1) Trial
    Silberstein, S. D.
    Kudrow, D.
    Saper, J.
    Janelidze, M.
    Smith, T.
    Dodick, D. W.
    Chakhava, G.
    Wilks, K.
    Schaeffler, B.
    Cady, R.
    Hirman, J.
    Smith, J.
    HEADACHE, 2018, 58 (08): : 1298 - 1298
  • [25] Eptinezumab for Prevention of Chronic migraine: Results of 2 Infusions in the Phase 3 PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) Trial
    Kudrow, David
    Lipton, Richard
    Silberstein, Stephen
    Cady, Roger
    Schaeffler, Barbara
    Biondi, David
    Smith, Jeff
    NEUROLOGY, 2019, 92 (15)
  • [26] EPTINEZUMAB RESULTS FOR THE PREVENTION OF EPISODIC MIGRAINE THROUGH 1 YEAR IN THE PHASE 3 PROMISE-1 (PREVENTION OF MIGRAINE VIA INTRAVENOUS EPTINEZUMAB SAFETY AND EFFICACY-1) TRIAL
    Dodick, D.
    Janelidze, M.
    Saper, J.
    Kudrow, D.
    Chakhava, G.
    Schaeffler, B.
    Cady, R.
    Hirman, J.
    Smith, J.
    CEPHALALGIA, 2018, 38 : 89 - 90
  • [27] EPTINEZUMAB FOR PREVENTION OF CHRONIC MIGRAINE (CM): RESULTS OF 2 INFUSIONS IN THE PHASE 3 PROMISE-2 (PREVENTION OF MIGRAINE VIA INTRAVENOUS EPTINEZUMAB SAFETY AND EFFICACY-2) TRIAL
    Ashina, M.
    Goadsby, P. J.
    Lipton, R. B.
    Azimova, J.
    Winner, P.
    Schaeffler, B.
    Biondi, D.
    Bhattacharya, S.
    Smith, J.
    Cady, R.
    CEPHALALGIA, 2018, 38 : 84 - 85
  • [28] Eptinezumab for the Prevention of Episodic Migraine Through 1 Year: Results from the Phase 3 PROMISE-1 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-1) Trial
    Saper, Joel
    Wilks, Kerri
    Chakhava, George
    Cady, Roger
    Schaeffler, Barbara
    Biondi, David
    Hirman, Joe
    Smith, Jeff
    NEUROLOGY, 2019, 92 (15)
  • [29] Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
    Smith, Timothy R.
    Janelidze, Marina
    Chakhava, George
    Cady, Roger
    Hirman, Joe
    Allan, Brent
    Pederson, Susan
    Smith, Jeff
    Schaeffler, Barbara
    CLINICAL THERAPEUTICS, 2020, 42 (12) : 2254 - +
  • [30] Eptinezumab for Prevention of Chronic Migraine (CM): Results of 2 Quarterly Intravenous Infusions in the Phase 3 PROMISE-2 (PRevention of Migraine via Intravenous Eptinezumab Safety and efficacy-2) Trial
    Lipton, R. B.
    Goadsby, P. J.
    Azimova, J.
    Ashina, M.
    Spierings, E. L. H.
    Winner, P. K.
    Schaeffler, B.
    Biondi, D.
    Bhattacharya, S.
    Smith, J.
    Cady, R.
    HEADACHE, 2018, 58 (08): : 1300 - 1300
12345